Disc Medicine reports FY2022 net loss $46.8M; cash $194.6M; bitopertin Phase 2 trials ongoing

Disc Medicine, Inc.

2023-Q1 EPS reported -$1.20

Net loss of $46.8M for FY2022 vs $36.0M in 2021; R&D expenses $33.4M, G&A $14.0M.
Cash and equivalents $194.6M as of Dec 31, 2022, up from $88.0M; expects to fund operations into 2025.
Bitopertin Phase 2 BEACON (EPP/XLP) interim data expected 1H 2023; AURORA topline data by end 2023.
DISC-0974 Phase 1b/2 in MF and NDD-CKD initiated; interim data expected end 2023.
Annual meeting June 9, 2023; record date April 14; stockholder proposal deadline April 10.

item 2.02 item 5.08 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Disc Medicine, Inc. reported financial results for the full year ended December 31, 2022.

Period: the full year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 31, 2023, Disc Medicine, Inc. (the “Company”) announced its financial results for the quarter and fiscal year ended December 31, 2022 and provided a corporate update.

View on SEC.gov

Browse all earnings releases →

Disc Medicine, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-086710

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.